Evidence map›Paper›PMID 42770297›Full record

ArticleJCI insight2026

Proximal tubule ACE2 mediates early responses to hypertension by regulating intrarenal RAS and sodium homeostasis.

Jacqueline M Emathinger, Zhidan Xiang, Jonathan W Nelson, Matthew W Hagen, Nakyung Kim, David I Ortiz-Melo, Natalie Mattocks, Jorge F Giani, Dexter L Lee, Hannah Hartman-Houstman and 6 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jacqueline M EmathingerDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Zhidan XiangDivision of Nephrology, Department of Medicine, Duke University and Durham VA Health Care Centers, Durham, North Carolina, USA.
Jonathan W NelsonDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Matthew W HagenDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Nakyung KimDivision of Nephrology and Hypertension, Department of Medicine, Keck School of Medicine, University of Southern California, USA.
David I Ortiz-MeloDivision of Nephrology, Department of Medicine, Duke University and Durham VA Health Care Centers, Durham, North Carolina, USA.
Natalie MattocksDivision of Nephrology, Department of Medicine, Duke University and Durham VA Health Care Centers, Durham, North Carolina, USA.
Jorge F GianiDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Dexter L LeeDepartment of Physiology and Biophysics, College of Medicine, Howard University, Washington, DC, USA.
Hannah Hartman-HoustmanDepartment of Physiology and Neuroscience, Keck School of Medicine, and.
Donna L RalphDepartment of Physiology and Neuroscience, Keck School of Medicine, and.
Alicia A McDonoughDepartment of Physiology and Neuroscience, Keck School of Medicine, and.
Brianna ChenClinical Pharmacy and Experimental Therapeutics Program, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
Stan G LouieClinical Pharmacy and Experimental Therapeutics Program, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
Thomas M CoffmanDivision of Nephrology, Department of Medicine, Duke University and Durham VA Health Care Centers, Durham, North Carolina, USA.
Susan B GurleyDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.

Funding

Oregon Clinical and Translational Research Institute TL1 ProgramTL1TR002371 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ALLISON Deborah FRYER, JESSINA C MCGREGOR · 2017 to 2026
$6.2M
Renal Genomics CoreP30DK096493 · NIDDK · DUKE UNIVERSITY · PI FOSTER, MARY H., SVETKEY, LAURA P · 2012 to 2016
$5.9M
Actions of Angiotensin II Along the Nephron to Regulate Blood PressureR01DK098382 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GURLEY, SUSAN BAILEY · 2014 to 2025
$3.8M
Medical Scientist Training Program of Oregon Health & Science UniversityT32GM109835 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI JACOBY, DAVID B · 2016 to 2020
$1.1M
Renal Pericytes as a Target for Angiotensin II Signaling in HypertensionK01DK121737 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NELSON, JONATHAN W · 2020 to 2024
$669k
NCATS NIH HHS TL1 TR002371NIDDK NIH HHS K01 DK121737NIDDK NIH HHS P30 DK096493NIDDK NIH HHS R01 DK098382NIGMS NIH HHS T32 GM109835
6 · The paper itself

Abstract

ACE2 is a membrane-bound monocarboxypeptidase strongly expressed in the renal proximal tubule (PT) with high affinity to degrade the vasopressor angiotensin II (AngII). We employed a mouse model of PT-specific ACE2 deletion (PT ACE2-KO) to demonstrate that the renal PT is a critical site for ACE2 regulation of blood pressure (BP) via modulation of the intrarenal renin-angiotensin system (RAS). While deletion of ACE2 from the PT had a minimal effect on baseline physiology, PT ACE2-KO mice were more susceptible to AngII hypertension than control mice. At day 5 of AngII infusion, the enhanced BP response was associated with cardiac hypertrophy, increased renal AngII levels, failure to suppress epithelial sodium channel (ENaC) γ cleavage, and increased sodium pump activity in PT ACE2-KO mice. Control mice instead increased renal ACE2 expression to reduce renal AngII accumulation and suppress intrarenal RAS activation, which offered protection from hypertension and complications. Transcriptional analysis corroborated changes in intrarenal RAS components and revealed alterations in distinct physiological pathways during AngII hypertension in PT ACE2-KO mice. Our studies provide evidence for alterations in ENaC regulation to contribute to the development of AngII hypertension and support PT-derived ACE2 as an integral member of the intrarenal RAS.

Indexed as

Angiotensin-Converting Enzyme 2HypertensionKidney Tubules, ProximalPeptidyl-Dipeptidase ARenin-Angiotensin SystemSodiumAngiotensin IIAnimalsBlood PressureDisease Models, AnimalEpithelial Sodium ChannelsHomeostasisMaleMiceMice, KnockoutAce2 protein, mouseAngiotensin-Converting Enzyme 2Angiotensin IIEpithelial Sodium ChannelsPeptidyl-Dipeptidase ASodiumCardiologyHypertensionMouse modelsNephrologySodium channels

Identifiers

PMID42770297
PMCPMC13596715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.